The U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a novel oral antibiotic, for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women and children aged 12 years and older, weighing 40 kg or more. This approval marks a significant breakthrough in the fight against uUTIs, particularly given the increasing antibiotic resistance associated with existing treatments.

Blujepa is the first-in-class oral antibiotic developed to combat uUTIs caused by various bacterial pathogens, including Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis. GlaxoSmithKline was granted approval following promising results from two Phase 3 clinical trials, EAGLE-2 and EAGLE-3.

Clinical Trial Success

The efficacy of Blujepa was demonstrated in these large-scale trials, comparing its effectiveness against nitrofurantoin, a widely used antibiotic for uUTIs. The EAGLE-2 study found that therapeutic success occurred in 50.6 per cent of patients taking Blujepa, compared to 47.0 per cent of those treated with nitrofurantoin. Meanwhile, the EAGLE-3 trial showed Blujepa’s superiority, with 58.5 per cent of patients achieving therapeutic success, compared to just 43.6 per cent in the nitrofurantoin group.

While Blujepa was generally well tolerated, some participants reported mild to moderate gastrointestinal side effects, including diarrhoea (16 per cent) and nausea (9 per cent). Severe gastrointestinal issues were rare, occurring in less than 1 per cent of patients. Each treatment arm in the trials had one reported serious drug-related adverse event.

GSK’s Chief Scientific Officer, Tony Wood, explained the importance of this approval, stating, “The approval of Blujepa is a crucial milestone, with uUTIs among the most common infections in women. We are proud to have developed Blujepa, the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections and rising rates of resistance to existing treatments.”

What Are Urinary Tract Infections?

Urinary tract infections are among the most prevalent bacterial infections, particularly affecting women. Symptoms of a UTI include:

• A strong, persistent urge to urinate
• A burning sensation while urinating
• Passing frequent, small amounts of urine
• Cloudy, dark, or strong-smelling urine
• Pelvic pain in women, particularly around the lower abdomen

If left untreated, uUTIs can lead to more severe kidney infections, which may cause fever, chills, nausea, and back pain.

Alternative Treatments and Prevention

While antibiotics like Blujepa are a primary treatment for uUTIs, several other approaches can help manage or prevent these infections:

• Hydration: Drinking plenty of water helps flush bacteria from the urinary tract.
• Cranberry Supplements: Some studies suggest cranberry products may help prevent UTIs by preventing bacterial adhesion to the bladder wall.
• Probiotics: Lactobacillus-based probiotics can support a healthy urinary microbiome and reduce recurrence.
• Hygiene Practices: Wiping from front to back and urinating after intercourse can help prevent bacterial spread.

Blujepa’s approval provides a promising new option for patients, particularly those facing recurrent infections or resistance to existing antibiotics.

Get Latest News Live on Times Now along with Breaking News and Top Headlines from Health and around the world.